Formulation and Evaluation of Telmisartan Sustained-Release Tablets

Abstract

The study concentrates on developing and accessing extended-release floating tablets that include Telmisartan, a medication typically prescribed for treating hypertension. Different polymer ratios were utilized in creating various formulations through direct compression methods to regulate the release of the drug. Quality assurance measures encompassed testing pre-compression and post-compression parameters such as hardness, friability, and drug content. One of the formulations, F5, stood out for its optimal drug release, reaching an impressive 97% over 20 hours. The stability studies performed on F5 revealed no notable alterations within three months under ICH conditions, thus verifying the formulation's strength. The results suggest that the improved formulation can improve patient adherence and maximize drug absorption, offering promising advantages in the effective treatment of hypertension through prolonged medication effectiveness.